Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Moodys
Queensland Health
Novartis
Fuji
Mallinckrodt
Covington
AstraZeneca
Healthtrust
Boehringer Ingelheim

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020616

« Back to Dashboard

NDA 020616 describes KADIAN, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from nine suppliers. Additional details are available on the KADIAN profile page.

The generic ingredient in KADIAN is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 020616
Tradename:KADIAN
Applicant:Allergan Sales Llc
Ingredient:morphine sulfate
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 020616
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 020616
Suppliers and Packaging for NDA: 020616
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616 NDA Allergan, Inc. 0023-6011 0023-6011-60 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0023-6011-60)
KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616 NDA Allergan, Inc. 0023-6012 0023-6012-60 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0023-6012-60)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Jul 3, 1996TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength50MG
Approval Date:Jul 3, 1996TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Jul 3, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020616

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-004 Mar 9, 2001 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-006 Oct 27, 2006 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-008 Apr 20, 2007 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-002 Jul 3, 1996 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-007 Feb 27, 2007 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-003 Jul 3, 1996 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-006 Oct 27, 2006 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-003 Jul 3, 1996 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-007 Feb 27, 2007 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-008 Apr 20, 2007 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Merck
Fish and Richardson
Harvard Business School
Novartis
Cantor Fitzgerald
Dow
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot